GENERI BIOTECH s.r.o.

Generi Biotech specializes in in vitro diagnostic (IVD) devices, including IVD kits and reagents for genetic and pharmacogenetic testing. Its products cover assays like TPMT, CYP2C19, DPYD, HLA-B*27, and lactose intolerance screening, as well as warfarin-related genetic markers. These devices are designed for personalized medicine applications, helping to tailor medical treatments based on individual genetic profiles.

Generi Biotech is based in the Czech Republic, which places its devices under the European Union’s regulatory framework. Since its products are listed in the EU’s eudamed registry, they are intended for use within the EU market. The company’s location and regulatory listings indicate compliance with EU IVD device requirements, ensuring its products meet necessary standards for distribution and use in the region.

Generi Biotech’s devices are listed in the eudamed registry, the official EU database for medical devices. This listing is important because it demonstrates transparency and compliance with EU regulations, allowing healthcare professionals, authorities, and patients to verify the device’s authorized status under the EU’s In Vitro Diagnostic Regulation (IVDR). It also facilitates traceability and ensures the devices meet required safety and performance standards.

Generi Biotech’s devices fall under Class C and IVD General classifications. Class C devices are typically higher-risk diagnostics requiring stricter regulatory scrutiny, while IVD General devices are classified based on their intended use and risk level. The classification determines the regulatory pathway, documentation requirements, and oversight needed to ensure the devices are safe and effective for their intended diagnostic purposes.